| Effects of CP-060S, a novel cardioprotective drug, on cardiac function and myocardial oxygen consumption. | |
| | |
MedLine Citation:
|
PMID: 9888255 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
1. We examined the effects of CP-060S on cardiac function and myocardial oxygen consumption (MVO2) in anesthetized dogs. 2. CP-060S (10-300 microg/kg i.v.) decreased heart rate, increased aortic flow and decreased mean blood pressure in a dose-dependent manner. The PR interval was significantly prolonged by administration of CP-060S (300 microg/kg i.v.). 3. CP-060S (10-300 microg/kg i.v.) increased coronary blood flow in a dose-dependent manner. Left ventricular end-diastolic pressure and maximal first derivative of left ventricular pressure were not significantly affected. 4. CP-060S (10-300 microg/kg i.v.) increased coronary sinus blood flow and decreased arteriovenous oxygen difference and MVO2 in a dose-dependent manner. 5. The effects of CP-060S on cardiac function and MVO2 are qualitatively similar to those of diltiazem, a typical Ca2+ antagonist. |
| | |
Authors:
|
Y Suzuki; M Akima; K Tamura |
Related Documents
:
|
22225805 - Pressure-accelerated dissociation of amyloid fibrils in wild-type hen lysozyme. 7671355 - Early morning reduction in ischemic threshold in patients with unstable angina and sign... 7877525 - Segmental blood flow through intramyocardial coronary arteries during ventricular systole. 8143305 - Accounting for the gregg effect in tetanised coronary arterial pressure-flow relationsh... 15547965 - Experimental study on transient behavior of semi-open two-phase thermosyphon. 3411675 - Urodynamic studies in acupuncture for women with frequency, urgency and dysuria. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: General pharmacology Volume: 32 ISSN: 0306-3623 ISO Abbreviation: Gen. Pharmacol. Publication Date: 1999 Jan |
Date Detail:
|
Created Date: 1999-03-12 Completed Date: 1999-03-12 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7602417 Medline TA: Gen Pharmacol Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 57-63 Citation Subset: IM |
Affiliation:
|
Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan. suzukiysy@gt.chugai-pharm.co.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Anti-Arrhythmia Agents / pharmacology* Blood Pressure / drug effects Dogs Heart / drug effects*, physiology Heart Rate / drug effects Male Myocardium / metabolism Oxygen Consumption / drug effects* Sodium Channels / drug effects Thiazoles / pharmacology* Thiazolidines |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Arrhythmia Agents; 0/CP 060S; 0/Sodium Channels; 0/Thiazoles; 0/Thiazolidines |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cyclic GMP-independent mechanisms of nitric oxide-induced vasodilation.
Next Document: Pseudocholinesterase-activity reduction during cardiopulmonary bypass: the role of dilutional proces...